Advertisement

Search Results

Advertisement



Article Topics

Your search for Ian E. Krop, MD, PhD matches 7 pages

Showing 1 - 7


breast cancer

ASCO Endorses Cancer Care Ontario Recommendations on Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decisions in Early-Stage, Operable Breast Cancer

As reported in the Journal of Clinical Oncology (JCO) by N. Lynn Henry, MD, PhD, of University of Michigan Comprehensive Cancer Center, Ann Arbor, and colleagues,1 ASCO has endorsed Cancer Care Ontario guideline recommendations on the role of patient and disease factors in decisions on adjuvant...

breast cancer

ASCO Endorses Cancer Care Ontario Recommendations on Decision-Making in Adjuvant Systemic Therapy for Early-Stage, Operable Breast Cancer

As reported in the Journal of Clinical Oncology by N. Lynn Henry, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and colleagues, ASCO has endorsed Cancer Care Ontario (CCO) guideline recommendations on the role of patient and disease factors in decisions on adjuvant systemic...

breast cancer

Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses abstract S2-02, “The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with estrogen receptor–positive, aromatase inhibitor–resistant advanced or metastatic...

breast cancer

Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data

Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.

Expert Point of View: Ian E. Krop, MD, PhD

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, Boston, commented on the findings by Ma et al in an interview with The ASCO Post, calling the study “very elegantly designed.” “The study provides three important pieces of information. One, it suggests that palbociclib can add to the benefit...

breast cancer

Ado-Trastuzumab Emtansine Improves Progression-Free Survival vs Physician’s Choice in Advanced HER2-Positive Breast Cancer

There are few treatment options for breast cancer patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic disease. In the open-label phase III TH3RESA trial reported in The Lancet Oncology by Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute,...

breast cancer

Acceptable Cardiac Safety of Ado-Trastuzumab Emtansine After Anthracycline-Based Chemotherapy in Early-Stage HER2-Positive Breast Cancer

In a study reported in the Journal of Clinical Oncology, Krop et al found that ado-trastuzumab emtansine (Kadcyla) had an acceptable cardiac safety profile when used after anthracycline-based (neo)adjuvant therapy in women with early-stage HER2-positive breast cancer. Study Details In the study,...

Advertisement

Advertisement



;
Advertisement